BrainsWay posts $5.0 million net profit for H1 2026, expands mental health investment portfolio
The company reported higher revenue and profit for the six months ended June 30, 2026, while continuing a series of minority investments in mental health service providers.
BrainsWay Ltd. reported a net profit of $5,000 thousand for the six months ended June 30, 20261, up from a net profit of $3,134 thousand in the same period of 2025, according to the company's condensed consolidated interim financial statements filed with the SEC. The company said its management and board of directors believe the company has sufficient funding to finance its business activity according to its plans in the foreseeable future.1
On the regulatory side, BrainsWay noted that in November 2025 the FDA cleared an expanded labeling of the company's system to treat adolescent (ages 15-21) MDD indications as an adjunct therapy, and also in 2025 the company obtained an expansion of its clearance to cover an accelerated treatment protocol for MDD.1
The filing also detailed continued expansion of the company's minority investment activity in mental health service providers through its subsidiary Tikva LLC. Regarding its stake in Neurolief, the company disclosed that on March 23, 2026, the company completed the second investment in Neurolief in the form of a $6 million convertible loan, following the achievement of the applicable FDA approval milestone.1 Separately, on March 12, 2026, the group made an additional $1.0 million investment pursuant to the original purchase agreement, following which the group's aggregate holding represented approximately 37.55% on a fully diluted basis.1 After the reporting period, on August 26, 2026, the group made an additional investment of $833 thousand pursuant to the agreement, after which its aggregate holding represented approximately 14.74% on a fully diluted basis.1
The company also entered new equity financing agreements during the period, including a May 12, 2026 agreement with APS Innovations LLC, the parent company of Advanced Psychiatric Management LLC, under which the group made an initial investment of $1.5 million for a minority position in Hopemark Health, representing approximately 6.4% on a fully diluted basis.1 Subsequent to the reporting date, on July 15, 2026, the company entered into a strategic equity financing agreement with CM Counsel Management LLC ("Sound Minds"), under which it will invest $500 thousand for a minority equity interest.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.